Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03319628
Title First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mersana Therapeutics

ovary epithelial cancer

fallopian tube cancer

peritoneal carcinoma

thyroid gland papillary carcinoma

papillary renal cell carcinoma

salivary gland cancer

lung non-small cell carcinoma

endometrial carcinoma



Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL | AUT

No variant requirements are available.